Illustration: Brendan Lynch/Axios
Agomab Therapeutics, a Belgian immune and inflammation biotech, raised $200 million in its IPO at $16 per share.
By the numbers: The offering puts Agomab's market cap at about $779.8 million, based on outstanding shares.
